Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).
Volume: 34, Issue: 15_suppl, Pages: 2509 - 2509
Published: May 20, 2016
Abstract
2509 Background: AR (BAY 94-9343) comprises a novel fully human anti-mesothelin IgG1 antibody conjugated to the maytansinoid tubulin inhibitor DMR. A phase I study was conducted in patients (pts) with advanced solid tumors. Methods: Eligible pts with solid tumors refractory to standard treatment, adequate organ function, and ECOG performance status (PS) ≤ 1 were enrolled. AR was administered IV on 2 schedules: every 21 days (q3w) in 45 pts (21...
Paper Details
Title
Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).
Published Date
May 20, 2016
Journal
Volume
34
Issue
15_suppl
Pages
2509 - 2509
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History